Search - tctmd.com

Displaying 21 - 40 of 2043

Sort: Relevancy | Date

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

News Conference News TCT 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

Yael L. Maxwell

October 27, 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

News Conference News TCT 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

Yael L. Maxwell

October 26, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

News Daily News

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

October 09, 2025

LAAO May Be an Option for Anticoagulated AF Patients With Breakthrough Stroke

News Daily News

LAAO May Be an Option for Anticoagulated AF Patients With Breakthrough Stroke

September 30, 2025

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

News Daily News

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Michael O'Riordan

September 23, 2025

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

News Industry News

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

September 15, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

News Daily News

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

August 12, 2025

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

July 24, 2025

Solid, Early Surgical Results With Polymer Mitral Valve

News Conference News NY Valves 2025

Solid, Early Surgical Results With Polymer Mitral Valve

July 02, 2025

Failure of ‘Jailed’ CIED Leads Not Uncommon After TTVR: TRIPLACE

News Conference News NY Valves 2025

Failure of ‘Jailed’ CIED Leads Not Uncommon After TTVR: TRIPLACE

June 27, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.